N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

@article{Farokhnia2013NacetylcysteineAA,
  title={N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.},
  author={Mehdi Farokhnia and Anita Azarkolah and Forod Adinehfar and Mohammad-Reza Khodaie-Ardakani and Seyed-Mohammad-Reza Hosseini and Habibeh Yekehtaz and M. H. Nssehzadeh Tabrizi and Farzin Rezaei and Bahman Salehi and S. Sadeghi and M Bakhtiari Moghadam and Fardin Gharibi and Omid Mirshafiee and Shahin Akhondzadeh},
  journal={Clinical neuropharmacology},
  year={2013},
  volume={36 6},
  pages={185-92}
}
OBJECTIVES Despite the burden of negative symptoms on quality of life in schizophrenic patients, no completely effective treatment has been developed to address such symptoms yet. Abnormalities in oxidative stress pathways have been recently demonstrated to be involved in the pathophysiology of schizophrenia, and a growing interest in antioxidant agents is emerging for targeting negative symptoms of schizophrenia. N-Acetylcysteine (NAC) is a potent antioxidant with neuroprotective properties… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com